# A Phase 3 Study of Tanezumab for Chronic Low Back Pain

> **NCT02528253** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1832 (actual)

## Conditions studied

- Low Back Pain

## Interventions

- **BIOLOGICAL:** Placebo to Week 16; tanezumab 5mg SC
- **BIOLOGICAL:** Placebo to Week 16, tanezumab 10 mg SC
- **BIOLOGICAL:** Tanezumab 5 mg SC
- **BIOLOGICAL:** Tanezumab 10 mg SC
- **BIOLOGICAL:** Tramadol PR oral

## Key facts

- **NCT ID:** NCT02528253
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-18
- **Primary completion:** 2017-10-17
- **Final completion:** 2018-12-20
- **Target enrollment:** 1832 (ACTUAL)
- **Last updated:** 2020-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02528253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02528253, "A Phase 3 Study of Tanezumab for Chronic Low Back Pain". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02528253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*